Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Human Endostatin Combined With Evafolimab Injection and Synchronal Radiochemotherapy for First-line Treatment of Locally Advanced Stage III Squamous Non-small Cell Lung Cancer

NCT06279754 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Xinxiang Medical College as lead sponsor.

NCT NCT06279754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06279754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Human Endostatin Combined With Evafolimab Injection and Synchronal Radiochemotherapy for First-line Treatment of Locally Advanced Stage III Squamous Non-small Cell Lung Cancer
Lead sponsor
The First Affiliated Hospital of Xinxiang Medical College
Phase
Phase 2
Overall status
Unknown status
Start date
February 18, 2024
Completion date
December 18, 2025
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced squamous non-small cell lung cancer